First in class monoclonal antibody potentiating human follicle stimulating hormone activity improves spermatogenesis in azoospermic rodent models
IGX12 is a first-in-class humanized monoclonal antibody (mAb) that potentiated FSH activity <i>in vitro</i> and stimulated spermatogenesis more effectively than gonadotropins alone in congenital and acquired azoospermia rodent models, even when increasing the dose of gonadotropins had no additional effect. These <i>in vitro</i> and <i>in vivo</i> findings suggest that IGX12 could have promise as a future treatment option for men with azoospermia and oligozoospermia.
Authors
- R Frydman
- Marie‐Christine Maurel (ORCID: https://orcid.org/0000-0001-5734-4750)
- Jérémy Decourtye
- Laurence Dupuy
- Sophie Casteret
- Philippe Bouchard (ORCID: https://orcid.org/0000-0002-9172-2476)
- Elodie Kara
Institutions
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- Services déconcentrés d'appui à la recherche Val de Loire (FR)
- Hôpital Foch (FR)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.3389/fendo.2025.1668945
- Primary Topic
- Reproductive Biology and Fertility
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement